July 29, 2013

Guideline Title

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing.

Bibliographic Source(s)

Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012 Apr;91(4):734-8. [40 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

Clinical pharmacogenetics implementation... [Clin Pharmacol Ther. 2012] - PubMed - NCBI

2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium.

Source

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.

Abstract

Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.